GT Capital
VC Fund
Shanghai, China
GT Capital is a fully market-oriented private equity investment platform under the Junyao Group-Aijian Group. It was jointly established by Aijian Group and Tang Zurong, Liu Dongjie, and Zhang Fan from China-US large investment banks and investment veterans in September 2017.Based on the "technology + people" concept, we invest incompanies driven by advanced technology and work closely with entrepreneurial teams with ambitious visions and strong execution capabilities.We are a professional investment organization that can provide excellent services to the investee companies. With the help of our strong shareholder resources, first-class institutional investor resources, and the strategic cooperation alliances we have built across regions and industries, Provide outstanding services in governance, strategic planning, and execution, business development, listing and mergers, and acquisitions.We have set up offices in Shanghai and Beijing, and will further set up new offices in Shenzhen and Chengdu. By then, the investment radius will cover economically active areas such as Beijing, East China, Guangshen, Chengdu and Chongqing.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries GT Capital invests in
Stages GT Capital invests in
Countries GT Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dongjie Liu
|
|||
Tang Zurong
|
|||
Zhang Fan
|
|||
Investment Focus
Industry
- Manufacturing 4 (40%)
- Semiconductor 4 (40%)
- Electronics 2 (20%)
- Health Care 2 (20%)
- Biotechnology 2 (20%)
Stage
- Series A 4 (40%)
- Series B 4 (40%)
- Series E 1 (10%)
- Venture - Series Unknown 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dongjie Liu
Managing Partner, Head of Risk Control and Compliance
|
Managing Partner, Head of Risk Control and Compliance | Total investments: 0 | Find email | |
|
Tang Zurong
Chairman and General Manager, Managing Partner
|
Chairman and General Manager, Managing Partner | Total investments: 0 | Find email | |
|
Zhang Fan
Managing Partner, Head of Investment Research
|
Managing Partner, Head of Investment Research | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Visinex Technology
|
Visinex Technology is a technology company that manufactures and develops application processor chips. | $43.9M / Venture - Series Unknown / Feb 26, 2026 | |
Zhixun Innovation
|
Zhixun Innovation provides one-stop medium and low-capacity storage solutions for domestic and foreign customers. | $14M / Series A / Sep 25, 2025 | |
|
Visinex Technology
|
Visinex Technology is a technology company that manufactures and develops application processor chips. | $13.9M / Series A / Jun 04, 2025 | |
Elite Technology
|
Elite Technology is a company that specializes in the development of chromatographic techniques, workstations, and high-performance liquid chromatography equipment for analysis, preparation, and industrial production. | $13.9M / Series A / May 15, 2024 | |
Pinzhou Technology
|
Pinzhou Technology focuses on the manufacturing of ultra-high purity stainless steel pipe fittings and research and development. | $14.1M / Series B / Dec 29, 2023 | |
TwinSolution
|
TwinSolution is a professional test interface product and solution provider in the semiconductor sector. | $23.2M / Series B / May 06, 2023 | |
Senko Mirco-electronics
|
Senko Micro-Electronics provides current detection chips, battery power monitoring, and measurement system-level solutions. They also produce current detection single chips for market applications such as transformers, series resistance detection, isolators, and more. | Series B / Jan 07, 2022 | |
Zhenge Biotech
|
Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation. | $51M / Series A / Mar 30, 2020 | |
Universal Medical Imaging
|
Universal Medical Imaging Diagnostic has partnered domestic hospitals to offer imaging devices for precise disease detection. | $85.9M / Series B / Feb 10, 2020 | |
CF PharmTech
|
CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effectivemanagement care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing. | $89.3M / Series E / Jan 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does GT Capital invest in?
GT Capital invests primarily in Manufacturing, Semiconductor and Electronics startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GT Capital?
Public channels for GT Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GT Capital?
The team at GT Capital includes Dongjie Liu (Managing Partner, Head of Risk Control and Compliance), Tang Zurong (Chairman and General Manager, Managing Partner) and Zhang Fan (Managing Partner, Head of Investment Research). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
